Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,987 | 8,735 | 250 | 4 | 0 |
| TOTAL | $9,086 | $10,350 | $260 | $13 | $0 |
| Non-Current Assets | |||||
| PPE Net | 34 | 13 | N/A | N/A | N/A |
| Other Non-Current Assets | 130 | 184 | 0 | 0 | 0 |
| TOTAL | $164 | $197 | $N/A | $N/A | $N/A |
| Total Assets | $9,250 | $10,547 | $260 | $13 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 374 | N/A | 0 |
| Accounts payable and accrued liabilities | 568 | 119 | 1,029 | 668 | 0 |
| Accrued Expenses | 22 | 15 | 118 | 107 | 0 |
| Other current liabilities | N/A | 174 | N/A | N/A | 0 |
| TOTAL | $1,089 | $809 | $1,770 | $1,024 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 250 | 347 | 0 |
| TOTAL | $N/A | $N/A | $250 | $347 | $N/A |
| Total Liabilities | $1,089 | $809 | $2,020 | $1,371 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 12,576 | 12,576 | 11,576 | N/A | N/A |
| Common Shares | 126 | 126 | 79 | 79 | 0 |
| Retained earnings | -9,238 | -7,457 | -4,794 | -4,392 | 0 |
| TOTAL | $8,161 | $9,738 | $-1,761 | $-1,358 | $0 |
| Total Liabilities And Equity | $9,250 | $10,547 | $260 | $13 | $0 |